News
LXRX
1.790
-1.65%
-0.030
Need To Know: Analysts Are Much More Bullish On Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Revenues
Simply Wall St · 2d ago
Piper Sandler Remains a Buy on Lexicon Pharmaceuticals (LXRX)
TipRanks · 4d ago
Lexicon Pharma Price Target Raised to $3.40/Share From $3.10 by Citigroup
Dow Jones · 5d ago
Lexicon Pharma Is Maintained at Buy by Citigroup
Dow Jones · 5d ago
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.4
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Geron (GERN) and Medacta Group SA (OtherMEDGF)
TipRanks · 5d ago
Lexicon Pharma Presents New Data Highlighting Cardiovascular Effects Of Dual SGLT1/2 Inhibitor, Sotagliflozin, At AHA Scientific Sessions 2026
Benzinga · 5d ago
Weekly Report: what happened at LXRX last week (1102-1106)?
Weekly Report · 5d ago
Lexicon’s $3.1 Price Target Unchanged as STENO1 Data and SONATA-HCM Catalysts Support Buy Rating
TipRanks · 11/06 14:33
Lexicon management to meet with Cantor
TipRanks · 11/05 21:45
Lexicon (LXRX) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/05 19:16
Analysts Are Bullish on These Healthcare Stocks: Summit Therapeutics (SMMT), Lexicon Pharmaceuticals (LXRX)
TipRanks · 11/05 15:30
Lexicon Pharmaceuticals Q3 2026 Earnings Call Transcript
Benzinga · 11/05 14:48
*Lexicon Pharma 3Q Rev $11.3M >LXRX
Dow Jones · 11/05 12:00
Press Release: Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
Dow Jones · 11/05 12:00
Press Release: Lexicon Pharmaceuticals Reports -2-
Dow Jones · 11/05 12:00
*Lexicon Pharma 3Q Loss/Shr 3c >LXRX
Dow Jones · 11/05 12:00
*Lexicon Pharma 3Q Loss $14M >LXRX
Dow Jones · 11/05 12:00
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 11/04 12:55
Weekly Report: what happened at LXRX last week (1026-1030)?
Weekly Report · 11/02 09:32
More
Webull provides a variety of real-time LXRX stock news. You can receive the latest news about Lexicon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXRX
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.